GlassScriptPhysician profile
Stephanie A Traxinger
NPI 1366608465
$2,602.86
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $415 · 2021: $922 · 2022: $816 · 2023: $14.85 · 2024: $84.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $84.99 · Food and Beverage: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $84.99 |
| Food and Beverage | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $436.52 | 2019-2022 | |
| Astellas Pharma US INC | $401.74 | 2019-2024 | Veozah |
| Amgen INC. | $376.31 | 2019-2022 | |
| Lilly USA, LLC | $282.72 | 2019-2022 | |
| Pfizer INC. | $202.75 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $202.31 | 2020-2022 | |
| Abbvie INC. | $128.17 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $99.54 | 2019-2022 | |
| Abbott Laboratories | $83.32 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $75.15 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $68.24 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $57.50 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.35 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $37.60 | 2020-2022 | |
| Allergan, INC. | $36.61 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.60 | 2022 | |
| Glaxosmithkline, LLC. | $16.42 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.99 | 2022 | |
| Amarin Pharma, INC. | $14.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Traxinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.